Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2016 August;151(4) > Giornale Italiano di Dermatologia e Venereologia 2016 August;151(4):432-5

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Per citare questo articolo

 

SPECIAL ARTICLES   

Giornale Italiano di Dermatologia e Venereologia 2016 August;151(4):432-5

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines

Gianfranco ALTOMARE 1, Fabio AYALA 2, Federico BARDAZZI 3, Gilberto BELLIA 4, Sergio CHIMENTI 5, Delia COLOMBO 4, Maria L. FLORI 6, Giampiero GIROLOMONI 7, Giuseppe MICALI 8, Aurora PARODI 9, Ketty PERIS 10, Gino A. VENA 11

1 Galeazzi Institute for Scientific Research, University of Milan, Milan, Italy; 2 Dermatology Clinic, Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy; 3 Dermatology Unit, Department of Diagnostic and Experimental Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; 4 Novartis Farma, Origgio, Varese, Italy; 5 Department of Dermatology, Tor Vergata University, Rome, Italy; 6 Dermatology Unit, Department of Clinical Medicine and Immunology, University of Siena, Siena, Italy; 7 Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy; 8 Dermatology Clinic, University of Catania, Vittorio Emanuele University Hospital, Catania, Italy; 9 Section of Dermatology, San Martino Institute for Scientific Research and University Hospital, Genoa, Italy; 10 Department of Dermatology, Sacro Cuore Catholic University, Rome, Italy; 11 Private Practitioner, Bari, Italy


PDF


Cyclosporine (CsA) is an effective and safe therapeutic option in various dermatoses in both adults and children. Over the last 25 years, Italian dermatologists have gained relevant experience about the use of CsA in the treatment of psoriasis and atopic dermatitis, and an Italian Consensus Conference has recently provided recommendations in adult patients. A comparison between these real-world indications and current European guidelines is hereby provided.

inizio pagina